ATX-304 Beyond Fat Loss: Cholesterol, Liver Fat, and Metabolic Health

Most conversations about ATX-304 focus on how much weight someone might lose.

But I think that leaves out one of the most interesting parts of the research.

What if the meaningful changes begin before the scale moves very much?

ATX-304 is an investigational oral small molecule, previously studied as O304. Its research program examines AMPK activation and mitochondrial activity in metabolic disease. The question extends beyond body weight to how the body handles fuel.

That is why its cholesterol and broader metabolic findings deserve a closer look.

There is one distinction we need to keep clear: the specific cholesterol-lowering finding discussed here comes from animal research. The newer human findings concern other metabolic measures, including triglycerides and fat distribution.

AMP-activated protein kinase, or AMPK, helps coordinate cellular responses to energy availability.

Among its targets is HMG-CoA reductase, an enzyme involved in cholesterol synthesis. AMPK can phosphorylate this enzyme, reducing its activity.

Researchers tested the importance of that relationship in mice engineered so that HMG-CoA reductase could no longer respond normally to AMPK phosphorylation. The animals showed increased cholesterol synthesis and disturbances in liver metabolism.

That provides a biological reason to investigate AMPK in cholesterol regulation.

But it does not tell us that every AMPK-active compound lowers cholesterol through the same mechanism—or that a response in mice predicts a particular LDL reduction in people.

AMPK and cholesterol synthesis research (opens in a new tab)

A 2025 study examined ATX-304 in mice with diet-induced progressive fatty liver disease.

Total blood cholesterol averaged approximately 212 mg/dL in untreated diseased mice versus 143 mg/dL in treated mice. Healthy controls averaged 114 mg/dL.

The treated animals also had lower body fat and improvements in liver fat and aspects of fibrosis, although liver responses were uneven.

Here is the important mechanistic detail: the researchers considered increased liver uptake a more likely explanation for the lower circulating cholesterol than reduced synthesis in this model.

Total liver cholesterol actually increased, alongside changes in cholesterol storage and handling. The authors interpreted the restored esterified-cholesterol pattern as evidence of improved handling capacity.

So describing ATX-304 as simply “turning off cholesterol production” would miss what this experiment suggested.

These were total-cholesterol findings in mice—not a demonstrated human LDL or ApoB reduction, and not proof of cardiovascular protection.

ATX-304 liver and cholesterol study (opens in a new tab)

Cambrian reported results from a Phase 1b trial involving 23 adults with obesity and prediabetes, with eight weeks of randomized treatment and an optional eight-week open-label extension.

Its June 2026 report described:

• Circulating triglycerides: Decreased

• Liver fat measured by MRI: Decreased

• Visceral adipose tissue: Decreased

• Adiponectin: Increased

• Resting metabolic rate: Increased by 8%

The company reported minimal weight loss at the exposure studied.

These findings were presented as conference data and summarized by the developer. This was a small, early trial, not a long-term outcomes study.

Triglycerides and cholesterol are different measurements. A triglyceride reduction should not be presented as proof that human LDL cholesterol fell.

Cambrian Phase 1b results announcement (opens in a new tab)

My interpretation is that the program deserves to be evaluated through more than a weight-loss headline.

If the purpose of a study is to understand metabolic health, the questions should include where changes occur and which measurements move—not just the number of pounds lost.

The early human pattern makes that discussion worthwhile. It does not establish that the effects are completely independent of changes in body composition; that requires appropriately designed studies.

It also changes how I would frame the fat-loss claims.

The evidence supports investigating ATX-304 for weight loss and metabolic disease. It does not yet justify presenting substantial fat loss as an established human outcome at the exposure used in that small trial.

The earlier O304 program included a 28-day randomized trial in 65 people with type 2 diabetes taking metformin.

The publication reported improvements in fasting glucose, an insulin-resistance estimate called HOMA-IR, and blood pressure. Glucose analyses included a post hoc subgroup; the microvascular-perfusion findings were strongest in participants with poorer perfusion at baseline.

Average blood-pressure changes in the treated group were approximately −5.8 mmHg systolic and −3.8 mmHg diastolic from baseline. The placebo group had small increases.

These are preliminary metabolic and vascular findings in a specific population. They do not demonstrate fewer heart attacks, strokes, or diabetes complications.

O304 human proof-of-concept study (opens in a new tab)

This is where enthusiasm needs to stay connected to the actual question being studied.

A laboratory value can be useful without telling us the whole clinical story.

To establish a broader health benefit, we would want larger controlled trials, durable effects, and a clearer understanding of which patients benefit and what tradeoffs accompany treatment.

For cholesterol specifically, we need human data that distinguish total cholesterol, LDL-C, HDL-C, non-HDL-C, and ApoB. A change in one should not stand in for all the others.

ATX-304 remains investigational. The current findings do not establish it as a replacement for prescribed lipid treatment or as a proven way to prevent cardiovascular disease.

The reason I find ATX-304 interesting is the possibility that its value could extend beyond changes in appearance or scale weight.

The cholesterol experiment offers a specific preclinical signal. The human program raises broader questions about lipid metabolism, fat distribution, glucose regulation, and vascular function.

Those questions deserve investigation on their own terms.

More studies will be conducted on Atx-304 and a greater understanding of the compound may bring even more benefits. Could Atx-304 be safe to use for longer durations and run alongside a GLP1 journey for better results? I think so, but isn't a claim I can state as factual yet.

— Beardedmuscle